Financial PerformanceSIBN delivered an impressive Q beating top- and bottom-line expectations, including a second consecutive quarter of adj. EBITDA positivity.
Product LaunchThe launches of its Granite 9.5 and TNT product have exceeded expectations, showing promising engagement with interventional spine doctors.
Regulatory ApprovalsSIBN has received FDA Breakthrough Device Designation for its new Pelvic Fracture Fixation System, exceeding launch expectations and making SIBN the only public company in its industry granted three BDDs.